Broxil was followed a year later by Methicillin (or Celbenin), an acid-labile penicillin which required to be given by intramuscular injection. We know of no published reports of its use in gonorrhoea, but a small personal trial in penicillin-resistant gonorrhoea showed that even multiple injections were completely ineffective. The outstanding property of Celbenin is its total resistance to penicillinase and its activity against bacteria other than staphylococci is low.
Broxil and Celbenin were followed in 1961 by Penbritin 6 (D (-) a -aminophenylacetamido) penicillanic acid (Ampicillin). Like Broxil, Penbritin is acid-stable and can thus be given orally. After a single dose of 1 g. the blood level rises comparatively slowly to reach a peak of between 6 and 7 t±g./ml. 2 hours after administration, significant concentrations being still present after 6 hours (Figs 1 and 2 ). Like other penicillins Penbritin is bactericidal and has a wide range of activity against both Grampositive and Gram-negative organisms. No data were available concerning the activity of the new compound against the gonococcus, and a trial in the treatment of gonorrhoea in the male was started in February, 1962. The organisms tested showed a wide variation in sensitivity both to Penbritin and to penicillin G. (Fig. 3) . In general, sensitivity to Penbritin and penicillin G. ran parallel (Fig. 4, opposite) . Thus, in 91 of the strains examined, the organism was equally sensitive to both penicillin G. and Penbritin. However, 37 strains were found to be more sensitive to penicillin G. than to Penbritin, and in five strains the reverse was the case.
We were unable to confirm the findings of Odegaard (1962) who, comparing the sensitivity of 100 strains of gonococci to Penbritin and penicillin G., concluded that, "whereas Penbritin showed weaker effect against most strains of gonococci, it showed better effect than penicillin G. against the least sensitive strains".
Tests in vitro can be only a rough guide to results in vivo. Patients failing to respond to P.A.M. may respond to Penbritin and vice versa, although sensitivity of the strain may be identical.
Only two patients complained of side-effects: one developed a transient urticaria, and the second vomited shortly after taking the capsules and complained of dizziness and severe skin irritation but soon recovered.
There were ten failures in the series-a failure rate of 5 per cent. This is considerably lower than that reported with any previous preparation of oral penicillin. All the failures but one were with less sensitive strains, though certainly not with the least sensitive strain in the series. As absorption of the drug is only maximal when taken on an empty stomach, variable absorption may explain the lack of a closer correlation between results in vivo and in vitro.
During the earlier part of the trial, when four of the failures occurred, three were successfully retreated with a single injection of 600,000 units P.A.M. The fourth case failed to respond to P.A.M. but was successfully re-treated with tetracycline. On the other hand, three of four P.A.M. failures which occurred during this period were successfully retreated with Penbritin; the fourth was re-treated with tetracycline by mistake.
The remaining six failures were re-treated with two doses of Penbritin-1 g. followed by 1 g. 4 hours later-and all six were successful. 
